Praxis Precision Medicines

This study tests an investigational drug called relutrigine in 160 children with a severe form of epilepsy called developmental and epileptic encephalopathy (DEE). The goal is to see if the drug can safely reduce monthly seizure frequency compared to a placebo. After the initial …

This trial is testing an experimental drug called PRAX-222 in children aged 2 to 18 who have a rare, severe form of epilepsy caused by changes in the SCN2A gene. The goal is to see if the drug is safe and can reduce how often seizures happen. Participants will receive either PRAX…

This study is testing the long-term safety of a once-daily drug called vormatrigine in 700 adults with focal or generalized tonic-clonic seizures. Participants must have already taken vormatrigine in a previous trial or program. The main goal is to check for side effects and chan…

This Phase 3 trial is testing whether the experimental drug vormatrigine can reduce the frequency of focal seizures in adults with epilepsy. About 300 participants who already take 1 to 3 seizure medications will receive either a low, medium, or high dose of vormatrigine or a pla…

This study tests a new medicine called PRAX-562 in 77 children with rare genetic epilepsies (SCN2A or SCN8A). The goal is to see if it safely reduces motor seizures. The trial has two parts: a double-blind phase where some children get the drug and some get a placebo, followed by…

This study tests whether a new drug called ulixacaltamide can safely reduce tremors and improve daily activities in adults with essential tremor. About 1,000 participants will receive either the drug or a placebo for up to 12 weeks, then may join a long-term safety study. The goa…